Development of new hepatitis E vaccines

Figures & data

Table 1. HEV candidate vaccines and commercialized vaccines.

Name	ORF2 range (aa)	Stage	Reference	Remark
Proteins expressed in prokaryotic system
p239	368–606	licenced	60, 61, 62	Hecolin®, genotype I strain, VLPs
P179	439-617	phase Ib clinical trial	57, 58, 59	genotype IV strain, VLPs
TrpE-C2	221–660	preclinical study	56	genotype I strain, fusion protein
Proteins expressed in baculovirus-infected system
GSK candidate vaccine	112-607	phase II clinical trial	65, 66, 67, 68	genotype I strain, 56kDa, VLPs
Bacmid-HEV ORF2	126-621	preclinical study	69	genotype IV strain, VLPs and non-VLPs
Proteins expressed in yeast
HP/HEV2.3	112-607	preclinical study	72	genotype IV, 56 kDa, VLPs
HEV ORF2	69-600	preclinical study	73	59kDa
Vectored vaccine against HEV
HEV truncated△(aa1-111)-ORF2	112-660	preclinical study	74, 75	AAV expression vector
tPAsp-PADRE-truncated ORF2	112-660	preclinical study	76	pVAX1 expression vector
Combined vaccine and recombinant chimeric vaccine
hepatitis A and E	439-617	preclinical study	77	Combined vaccine
HAV-HEp148	459-606	preclinical study	78	chimeric recombinant vaccine
HE-ORF2, HA-VP1,	368-607	preclinical study	79	chimeric recombinant vaccine
HEV-HBsAg	551-607	preclinical study	80	chimeric VLPs
GST-NoV P(-)-HEV P	452-617,	preclinical study	81	GST fusion proteins
HEV-RV-AstV	112-607	preclinical study	82	recombinant fusion protein
Oral immunization HEV vaccine
rHEV VLPs	112-660	preclinical study	84, 85	Recombinant VLPs, oral administration
plant-derived vaccine	394-604	preclinical study	87	In transgenic tomato